Kala Pharmaceuticals Inc (KALA NASDAQ) stock market data APIs
$5.8763
1.05(17.9%)
as of July 11, 2025
Try our APIs with
free plan!
Kala Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Prev. Close
5.8763
Open
6.9273
High
6.9273
Low
5.8763
52 wk Range
2.92-11.2
Market Cap
37 747 K
Shares Outstanding
6 452 K
EPS
-1.7414
Beta
-1.983
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kala Pharmaceuticals Inc data using free add-ons & libraries
Get Kala Pharmaceuticals Inc Fundamental Data
Kala Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -39 048 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -2.54
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kala Pharmaceuticals Inc News
New
Kala Bio completes enrollment in Phase 2b trial for KPI-012 in eye disorder
Kala Bio, Inc. (NASDAQ:KALA), a small-cap biotech with a market capitalization of $33.29 million, announced Wednesday the completion of patient enrollment in its CHASE Phase 2b clinical trial evaluati...
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...
KALA BIO to Present at Jefferies Global Healthcare Conference
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...
KALA BIO Announces Chief Executive Officer Transition
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovativ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
